Cardioxyl Pharmaceuticals. is leveraging its nitroxyl chemistry platform to develop drugs for unmet cardiovascular conditions. Its lead product just entered Phase I/II trials for acute decompensated heart failure.
11350 McCormick Road
Suite 901
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Coartem Baby to be rolled out in eight African countries in the autumn.
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
Public Company Edition: A breakthrough designation, data and deals prompted big follow-on public offerings in late June and early July, including $402.5m for Cidara, $250.8m for Kymera and $230m for Dyne. Also, Revolution Medicines accessed up to $2bn from Royalty Pharma.
